Literature DB >> 26318249

The human papillomavirus 16 European-T350G E6 variant can immortalize but not transform keratinocytes in the absence of E7.

Melissa Togtema1, Robert Jackson1, Christina Richard2, Sarah Niccoli3, Ingeborg Zehbe4.   

Abstract

Human papillomavirus type 16 is commonly implicated in HPV-related cancers. However, only a small number of infected individuals progress to this stage. Epidemiological evidence demonstrated that oncogenic risk is population-specific and variations within the viral oncogene, E6, have been suggested to play a role in these findings. Of focus in this study is the European-T350G variant, which is characterized by an L>V amino acid substitution at residue 83 of the prototype E6 protein. To elucidate the functional effects of this polymorphism, we followed keratinocytes transduced with E-T350G E6 for over 60 passages and compared them to keratinocytes transduced, in parallel, with prototype or Asian-American (Q14H/L83V/H78Y) E6. We found that although E-T350G E6 immortalized transduced keratinocytes in the absence of E7, these cells were not fully transformed. We also found that E-T350G down-regulated E-cadherin compared to the other variants, providing a possible link between its population-based oncogenicity and host genetic variations.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  E-T350G; E-cadherin; E6 protein; HPV16 variant; Human papillomavirus; Immortalization; Transformation

Mesh:

Substances:

Year:  2015        PMID: 26318249     DOI: 10.1016/j.virol.2015.07.025

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  An epithelial organoid model with Langerhans cells for assessing virus-host interactions.

Authors:  Robert Jackson; Statton Eade; Ingeborg Zehbe
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-05-27       Impact factor: 6.237

2.  Functional variants of human papillomavirus type 16 demonstrate host genome integration and transcriptional alterations corresponding to their unique cancer epidemiology.

Authors:  Robert Jackson; Bruce A Rosa; Sonia Lameiras; Sean Cuninghame; Josee Bernard; Wely B Floriano; Paul F Lambert; Alain Nicolas; Ingeborg Zehbe
Journal:  BMC Genomics       Date:  2016-11-02       Impact factor: 3.969

3.  The potential of RNA as a target for national screening of pre-cancer.

Authors:  Frank Karlsen; Margaret Muturi; Cosmas Muyabwa; Lars E Roseng; Serge Bigabwa; Byamungu Chihongola; Lucy Muchiri
Journal:  J Public Health Afr       Date:  2018-12-21

4.  High prevalence of human papillomavirus and European variants of HPV 16 infecting concomitantly to cervix and oral cavity in HIV positive women.

Authors:  Milagros Pérez-Quintanilla; Rocío Méndez-Martínez; Salvador Vázquez-Vega; Raquel Espinosa-Romero; Rita Sotelo-Regil; María Delia Pérez-Montiel; Ubaldo Ramos-Alamillo; Teresita de Jesús Cabrera-López; Salim Abraham Barquet-Muñoz; Carlos Pérez-Plascencia; Alejandro García-Carrancá; David Cantú de León
Journal:  PLoS One       Date:  2020-04-22       Impact factor: 3.240

5.  The T350G Variation of Human Papillomavirus 16 E6 Gene Prevails in Oropharyngeal Cancer from a Small Cohort of Greek Patients.

Authors:  Christine Kottaridi; Panagiota Resta; Danai Leventakou; Katerina Gioti; Ioannis Zygouras; Alina-Roxani Gouloumi; Georgios Sakagiannis; Khalid J Alzahrani; Maria S Venetikou; Fragkiski Anthouli-Anagnostopoulou; Apostolos Beloukas
Journal:  Viruses       Date:  2022-08-04       Impact factor: 5.818

Review 6.  Human papillomavirus genome variants and head and neck cancers: a perspective.

Authors:  Jean-Damien Combes; Silvia Franceschi
Journal:  Infect Agent Cancer       Date:  2018-04-10       Impact factor: 2.965

7.  Virus-Host Protein-Protein Interactions between Human Papillomavirus 16 E6 A1 and D2/D3 Sub-Lineages: Variances and Similarities.

Authors:  Guillem Dayer; Mehran L Masoom; Melissa Togtema; Ingeborg Zehbe
Journal:  Int J Mol Sci       Date:  2020-10-27       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.